Skip to content

Feasibility of Reduced-Extent Surgery After Neoadjuvant Therapy for Advanced Upper Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction: A Multicenter Retrospective Cohort Study

Feasibility Assessment of Reduced-Extent Surgery Following Neoadjuvant Therapy for Advanced Upper Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction: A Multicenter Retrospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120024
Enrollment
Unknown
Registered
2026-03-09
Start date
2026-03-09
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer or gastroesophageal junction cancer

Interventions

Gastric cancer or gastric-cardiac junction cancer observation group:None

Sponsors

Chinese Academy of Medical Sciences Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 20 - 80 years old, gender not restricted; 2. Diagnosed with adenocarcinoma through tissue biopsy; 3. ECOG score: 0 - 2; 4. ASA classification: I - III; 5. Undergone radical surgery + D2 lymph node dissection; 6. Received either simple chemotherapy or chemotherapy combined with immunotherapy before the surgery, and the total treatment course was >= 2 cycles; 7. No distant metastasis was found before the surgery (M0).

Exclusion criteria

Exclusion criteria: 1. Preoperative radiotherapy, targeted therapy or neoadjuvant treatment were not determined; 2. Multiple lesions in the stomach were present; 3. Distal metastasis of gastric cancer (M1 stage) was detected preoperatively or intraoperatively, or positive results from abdominal implantation metastasis or abdominal exfoliated cell examination were found; 4. History of other malignant tumors within 5 years; 5. Emergency surgery or palliative surgery; 6. Key clinical data were missing (lymph node station information was not clearly recorded in the pathological report, preoperative treatment plan was not clearly recorded in the medical record, etc.), which prevented analysis.

Design outcomes

Primary

MeasureTime frame
Survival rate without recurrence;

Secondary

MeasureTime frame
Overall survival ;Station 1–Station 12 lymph node metastasis rate;Index of lymph node treatment for each station;Pathological complete response rate;

Countries

China

Contacts

Public ContactYantao Tian

Chinese Academy of Medical Sciences Cancer Hospital

tianyantao@cicams.ac.cn+86 176 1104 0103

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026